National Institutes of Health

If you reside in the Kingston, Rhode Island area and are looking for an undergraduate or graduate program for academic study, why not check out the University of Rhode Island? Programs available to choose from as a major include the interesting Animal and Veterinary Science, Business Administration, Civil and Environmental Engineering, Geology and Geological Oceanography, Human Development and Family Studies, International Engineering, Journalism, and Nursing, among many others. URI has a festive student life which includes both entertainment events and organizations which can help students get a leg up in the career search. Study abroad programs are offered during the summer and school year. There is also a strong Greek life, Student Senate, dining, and athletic programs. Other services include a counseling center and health services. If you qualify for financial aid like the Centennial and University Scholarships, your entire tuition may be covered. There are also grants and loans that can help cover tuition and other educational expenses. When it comes time to search for a job, the career service center can help students with writing resumes, interview preparation, meeting potential employers, and much more.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

Brown University Endowment is the investment arm of Brown University, located in Providence, Rhode Island, and founded in 1764. The endowment consists of various individual funds, including both donor-restricted and corporate-designated funds, aimed at maintaining the university's purchasing power and providing a stable financial resource for its operations. It invests across a diverse range of asset classes, including public equity, fixed income, real estate, commodities, and alternative markets. The endowment employs strategies such as long/short hedging to optimize its investment performance. Managed by the Brown University Investment Office under the oversight of the board of trustees, the endowment plays a crucial role in supporting the university’s commitment to exceptional education and research, serving approximately 8,000 students across its undergraduate, graduate, and medical programs.

The Miriam Hospital is a private, not-for-profit hospital at 164 Summit Avenue in Providence, in the U.S. state of Rhode Island. It is a major teaching affiliate of the Warren Alpert Medical School of Brown University.

ProThera Biologics, Inc. is a biotechnology company based in Providence, Rhode Island, founded in 2001 by Dr. Yow-Pin Lim and Dr. Douglas C. Hixson. The company focuses on developing human plasma proteins and therapeutic products that modulate inflammation through natural serine protease inhibitors. ProThera Biologics specializes in inter-alpha inhibitor proteins aimed at treating various inflammatory diseases, including sepsis, cancer, and anthrax intoxication. The company's innovative approach includes the development of integrated theranostic and therapeutic biomolecules that not only address inflammation but also assist in tissue repair, enhancing treatment efficacy for life-threatening conditions. ProThera Biologics has established a strategic partnership with ProMetic Life Sciences Inc. to further advance its research and product development.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.